Kymera Therapeutics Strengthens Board of Directors with Appointment of People and Business Leader Leigh Morgan
July 08 2022 - 7:30AM
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage
biopharmaceutical company advancing targeted protein degradation to
deliver novel small molecule protein degrader medicines, today
announced the appointment of Leigh Morgan to its Board of
Directors. Ms. Morgan joins Kymera’s Board as a senior executive
accomplished in scaling global, profitable, high-performing
organizations.
“Leigh has distinguished herself as an expert in developing
world-class organizations in a wide variety of settings, and I’m
thrilled to welcome her to Kymera’s Board of Directors,” said Nello
Mainolfi, PhD, Co-Founder, President and Chief Executive Officer of
Kymera Therapeutics. “Given our aspirations to evolve Kymera into a
fully-integrated, global biopharmaceutical company, her extensive
background across critical business functions will provide our team
with an invaluable resource as we scale our operations and advance
as a best-in-class degrader medicines company.”
“A pioneer in the field of targeted protein degradation, Kymera
has rapidly transformed into a clinical stage company, and is now
dosing patients in multiple clinical programs in immunology and
oncology,” said Ms. Morgan. “I am excited to join the team and help
them continue their evolution and achieve their mission to bring
transformative medicines to the patients that need them.”
Ms. Morgan brings deep human resource, operations, strategy,
businesses and people integration, and public-private partnership
competencies to Kymera’s board. In her current role as Chief
Strategy and Operating Officer for Nia Tero, she is a key architect
of the firm’s growth, inclusive of strategy, finance, innovation,
communications, operations, impact investments and governance. Ms.
Morgan previously served as Chief Operating Officer of the Bill
& Melinda Gates Foundation where she oversaw a broad portfolio,
including human resources, information technology and security,
facilities and the foundation’s culture transformation efforts.
Her health and biotechnology leadership roles include serving as
Associate Chancellor at the University of California, San
Francisco, Vice President and Global Head of Human Resources for
Product Development at Genentech, and HR leadership roles at GSK.
She serves as Vice-Chair/Chair-elect of the Board at the Fred Hutch
Cancer Center, is on the University of Washington Medical Center
Advisory Board, and is an independent director at Curemark, a
clinical-stage biotechnology company. She holds a master’s degree
in organization development from the American University and a
bachelor’s degree from Duke University. She was awarded an honorary
doctorate from the Asian University for Women in Bangladesh and is
a member of the Council on Foreign Relations.
About Kymera TherapeuticsKymera Therapeutics
(Nasdaq: KYMR) is a biopharmaceutical company pioneering the field
of targeted protein degradation, a transformative approach to
address disease targets and pathways inaccessible with conventional
therapeutics. Kymera’s Pegasus platform is a powerful drug
discovery engine, advancing novel small molecule therapies that
harness the body’s innate protein recycling machinery to degrade
dysregulated, disease-causing proteins. With a focus on undrugged
nodes in validated pathways, Kymera is advancing a pipeline of
novel therapeutics designed to address the most intractable
pathways and provide new treatments for patients. Kymera’s initial
programs target IRAK4, IRAKIMiD, and STAT3 within the IL-1R/TLR or
JAK/STAT pathways, providing the opportunity to treat patients with
a broad range of immune-inflammatory diseases, hematologic
malignancies, and solid tumors. For more information, visit
www.kymeratx.com.Founded in 2016, Kymera is headquartered in
Watertown, Mass. Kymera has been named a “Fierce 15” biotechnology
company by Fierce Biotech and has been recognized by the Boston
Business Journal as one of Boston’s “Best Places to Work.” For more
information about our people, science, and pipeline, please visit
www.kymeratx.com or follow us on Twitter or LinkedIn.
Investor Contact:
Bruce Jacobs Chief Financial Officer
investors@kymeratx.com857-285-5300
Chris BrinzeyManaging Director,
Westwickechris.brinzey@westwicke.com339-970-2843
Media Contact:
Todd CooperSenior Vice President, Corporate
Affairsmedia@kymeratx.com 857-285-5300
Kymera Therapeutics (NASDAQ:KYMR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Kymera Therapeutics (NASDAQ:KYMR)
Historical Stock Chart
From Jul 2023 to Jul 2024